Cathepsin B Inhibitor Compounds for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies fail to effectively treat diseases associated with impaired β-galactosidase activity, particularly in the central nervous system, due to the inability of compounds to cross the blood-brain barrier and the lack of specificity towards cathepsin B inhibition.
Innovation Solution
Development of new cathepsin B inhibitors with specific chemical structures that enhance absorption, distribution, metabolism, and excretion, allowing them to penetrate the blood-brain barrier and inhibit cathepsin B, thereby addressing the underlying enzyme deficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic compounds are used, then they can be administered systemically, but they fail to cross the blood-brain barrier and treat central nervous system symptoms
Solution Approach 1:
The patent modifies molecular parameters of cathepsin B inhibitors to enhance their lipophilicity and reduce molecular weight, enabling them to cross the blood-brain barrier. Specific structural modifications include optimizing the balance between hydrophobic and hydrophilic regions of the molecules to achieve appropriate brain penetration while maintaining inhibitory activity.
2Reliability
If cathepsin B inhibitors are developed with enhanced brain penetration, then they can treat CNS symptoms, but they may lose specificity and inhibit other enzymes
Solution Approach 1:
The patent introduces specific local structural features in the inhibitor molecules that target the unique active site architecture of cathepsin B. These include specific S1 and S2 pocket interactions through tailored amino acid side chains that form hydrogen bonds and hydrophobic interactions exclusively with cathepsin B residues, ensuring selective inhibition despite enhanced brain penetration.
3Reliability
If existing compounds are used to inhibit cathepsin B, then they show some inhibitory activity, but they lack optimal drug-likeness properties for effective therapy
Solution Approach 1:
The patent systematically optimizes multiple molecular parameters simultaneously including molecular weight (150-500 Da), logP (1-4), hydrogen bond donors (0-3), and hydrogen bond acceptors (0-5) to achieve ideal drug-like properties. The compounds are designed with appropriate metabolic stability features and reduced toxicity risk while maintaining potent cathepsin B inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new cathepsin B inhibitors effectively treat diseases like GM-1 gangliosidosis and Morquio syndrome type B by improving drug-likeness and crossing the blood-brain barrier, providing therapeutic benefits for conditions previously untreatable with existing compounds.
Implementation Method 1
new cathepsin B inhibitors, which are effective in therapy... inhibit cathepsin B
Implementation Method 2
crossing the blood-brain barrier... providing therapeutic benefits for conditions previously untreatable
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention relates to new cathepsin B inhibitors, which are effective in therapy, and in particular in the treatment of diseases associated with an impaired activity of the β-galactosidase, such as GM-1 gangliosidosis, Morquio syndrome type B, Chediak-Higashi Syndrome, Galactosialidosis, Metachromatic leukodystrophy, Gaucher Disease, Alzheimer disease and traumatic brain injury.